CSI Market
Sign In | Register

Bellevue Life Sciences Acquisition (BLAC) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access BLAC quarterly Cash Flow →
Looking at cash flow data from Bellevue Life Sciences Acquisition through provides insight into Dec 31 2025's financial flexibility across reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022)
Operating Activities
Income-45.07
Depreciation & amortization0.01
Amortization of Other Assets9.30
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Severance Costs0.00
Provision For Loan Losses Expensed0.04
Increase (Decrease) in Inventories-0.77
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.50
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total0.12
Investment Income Interest-1.45
Operating Lease Expense0.12
Allowance For Bad Debts-
Interest Expense-
Noncash Merger Related Costs-
Gain On Change In Fair Value Of Financial Liabilities-
Income Tax Expense Benefit-
Increase Decrease In R O U Assets-
Increase Decrease In Operating Lease Liability-
Income taxes0.15
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts and Other Receivables-0.57
Increase (Decrease) in Accounts Payable, Trade-0.51
Increase (Decrease) in Accrued Liabilities0.48
Payments for (Proceeds from) Other Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.00
Other Working Capital-0.40
Other Noncash Income (Expense)0.00
Other net-9.05
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-4.33
Investing Activities
Capital Expenditures-0.18
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Gain Loss From Trust Account To Pay Expenses-
Cash Deposited In The Trust Account-
Proceeds From Trust Account For Payment To Redeeming Stockholders36.23
Increase In Longterm Loan-
Payments to Acquire Restricted Investments0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired1.22
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-2.64
Financing Activities
Short-term debt Net3.63
Other borrowing transactions0.00
Long-term debt - borrowings1.08
Long-term debt - repayments-1.17
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock6.06
Proceeds from Contributions from Affiliates0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Deferred Underwriting Fee Payable-
Offering Costs Partnership Interests-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents0.02
Capital Expenditures Incurred But Not Yet Paid-
Repayments To Affiliate-0.02
Extension Of Lease Liability-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities8.37
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-4.50
Total Cash Flow1.40
4 historic quarters locked

Sign in to unlock the full Bellevue Life Sciences Acquisition cash flow history.

Sign In Create Free Account

About Osr Holdings Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-037395

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License